Publications by authors named "Annalisa Biagi"
Article Synopsis
- * Understanding inherited traits is essential for making decisions regarding allogeneic hematopoietic cell transplants (allo-HCT) and choosing suitable donors.
- * The case of a 49-year-old woman with JAK2 V617F-positive primary myelofibrosis (PMF) illustrates the significance of genetic findings, including a variant in the SH2B3 gene, in clinical management and genetic counseling for transplant options.
Article Synopsis
- ATRA and ATO are the main treatments for low to medium risk acute promyelocytic leukaemia (APL), but many patients (60%) can have a side effect called leucocytosis, which means very high white blood cell counts.
- Researchers studied 65 APL patients and found that those with lower levels of important blood proteins (like fibrinogen) and higher amounts of cancer cells in their bone marrow were more likely to have leucocytosis when treated with ATRA and ATO.
- Leucocytosis can lead to other serious problems, so doctors need to keep a close eye on patients with these risk factors to help prevent issues and give extra treatments if needed.
Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability.
View Article and Find Full Text PDFArticle Synopsis
- In chronic lymphocytic leukemia (CLL), subclonal mutations below 10% to 15% variant allele frequency (VAF) have unclear clinical implications, but this study investigates their effect on patient survival and response to treatment.
- A comprehensive analysis of clinical features and mutation frequencies was conducted on two cohorts, with findings indicating that both high and low-VAF mutations were associated with significantly reduced overall survival compared to wild-type patients.
- The inclusion of low-VAF mutations provided better prognostic risk stratification in CLL than traditional models, suggesting a need to redefine what constitutes mutated CLL for improved clinical practice.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Am J Hematol
August 2021
Objectives: To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only.
Methods: A real-life cohort of 675 cases has been identified and investigated in the database of the groups participating in the study.
Results: At an unadjusted univariate analysis, a significant death risk reduction was observed favoring IB (IDELA-R vs IB HR = 0.
The introduction of agents inhibiting the BCR-associated kinases such as ibrutinib has dramatically changed treatments algorithms of chronic lymphocytic leukaemia (CLL) as well as the role of different adverse prognosticators. We evaluated the efficacy of ibrutinib as single agent, in a real-life context, on 180 patients with CLL mostly pre-treated, recruited from three independent cohorts from Italy. Patients received 420 mg oral ibrutinib once daily until progression or occurrence of unacceptable side effects.
View Article and Find Full Text PDFResponse to therapy is affected by the genetic heterogeneity of acute myeloid leukemia (AML) and persistence of leukemic cells below the threshold of morphological complete remission (mCR). Such persistence is called minimal (or measurable) residual disease (MRD). Areas covered: MRD assessment allows early identification of patients who are at high risk of relapse and who should timely receive aggressive therapy (e.
View Article and Find Full Text PDFBackground: CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed.
Design And Methods: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators.